Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short-term Investments (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Short-term Investments data on record, last reported at $62.8 million in Q4 2025.

  • For Q4 2025, Short-term Investments fell 52.08% year-over-year to $62.8 million; the TTM value through Dec 2025 reached $62.8 million, down 52.08%, while the annual FY2025 figure was $62.8 million, 52.08% down from the prior year.
  • Short-term Investments reached $62.8 million in Q4 2025 per TGTX's latest filing, up from $57.5 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $145.2 million in Q3 2024 and bottomed at $15.9 million in Q4 2021.
  • Average Short-term Investments over 5 years is $81.2 million, with a median of $64.5 million recorded in 2022.
  • Peak YoY movement for Short-term Investments: tumbled 69.46% in 2021, then skyrocketed 273.99% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $15.9 million in 2021, then surged by 273.99% to $59.4 million in 2022, then soared by 109.81% to $124.6 million in 2023, then rose by 5.24% to $131.1 million in 2024, then crashed by 52.08% to $62.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $62.8 million in Q4 2025, $57.5 million in Q3 2025, and $122.7 million in Q2 2025.